Cardiovascular health and economic effects of smoke-free workplaces / Michael K. Ong (2004)

Public Titre : Cardiovascular health and economic effects of smoke-free workplaces Type de document : texte imprimé Auteurs : Michael K. Ong, Auteur ; Stanton A. Glantz, Auteur Editeur : Excerpta Medica Inc. Année de publication : 2004 Collection : The American journal of medicine, ISSN 0002-9343 num. 117:1 Importance : p. 32-38 Présentation : tab. Langues : Anglais (eng) Catégories : [DIVERS] géographie:Amérique:Amérique du Nord:Etats-Unis [TABAC] étude [TABAC] tabagisme:aspect économique [TABAC] tabagisme:pathologie:pathologie cardio-vasculaire [TABAC] tabagisme:tabagisme passif:non-fumeur Index. décimale : TA 7.8 Lieux non-fumeurs Résumé : Abstract PURPOSE: Smoking is the leading controllable risk factor for heart disease. Only about 69% of U.S. indoor workers are currently covered by a smoke-free workplace policy. This analysis projects the cardiovascular health and economic effects of making all U.S. workplaces smoke free after 1 year and at steady state. METHODS: We estimated the number of U.S. indoor workers not covered by smoke-free workplace policies, and the effects of making all workplaces smoke free on smoking behavior and on the relative risks of acute myocardial infarctions and strokes. One-year and steady-state results were calculated using an exponential decline model. A Monte Carlo simulation was performed for a sensitivity analysis. RESULTS: The first-year effect of making all workplaces smoke free would produce about 1.3 million new quitters and prevent over 950 million cigarette packs from being smoked annually, worth about 2.3 billion dollars in pretax sales to the tobacco industry. In 1 year, making all workplaces smoke free would prevent about 1500 myocardial infarctions and 350 strokes, and result in nearly $60 [corrected] in savings in direct medical costs. At steady state, 6250 myocardial infarctions and 1270 strokes would be prevented, and $279 million [corrected] would be saved in direct medical costs annually. Reductions in passive smoking would account for 60% of effects among acute myocardial infarctions. CONCLUSION: Making all U.S. workplaces smoke free would result in considerable health and economic benefits within 1 year. Reductions in passive smoking would account for a majority of these savings. Similar effects would occur with enactment of state or local smoke-free policies. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8118

Exemplaires (1)

Code-barres	Cote	Support	Localisation	Section	Disponibilité
TA 005676	TA 7.8 ONG C	Article/Périodique	Bibliothèque FARES	Tabac	Consultation sur place Exclu du prêt

Aucun avis, veuillez vous identifier pour ajouter le vôtre !

Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers / Helene Faessel (2009)  

Public Titre : Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers : a multicenter, randomized, double-blind, placebo-controlled, parallel-group study Type de document : texte imprimé Auteurs : Helene Faessel, Auteur ; Patanjali Ravva, Auteur ; Kathryn Williams, Auteur Editeur : Excerpta Medica Inc. Année de publication : 2009 Collection : Clinical Therapeutics num. 31 (1) Importance : p.177-189 Note générale : Dans la bibliothèque virtuelle (articles scientifiques) Langues : Anglais (eng) Catégories : [DIVERS] discipline médicale, paramédicale et scientifique:pharmacologie [DIVERS] personne:famille:adolescent [TABAC] étude [TABAC] sevrage tabagique [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline Index. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Conclusions: Varenicline steady-state exposure in study subjects weighing >55 kg was similar to that observed previously in adults. The body-weight effect on varenicline pharmacokinetics, which resulted in higher exposure in individuals of smaller body size (<::55 kg), was adequately offset by administration of half the varenicline dose recommended in adults. Varenicline was generally well tolerated during the 14-day treatment period. En ligne : https://doi.org/10.1128%2Faac.42.8.2060 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=2709

Exemplaires (1)

Code-barres	Cote	Support	Localisation	Section	Disponibilité
TA 002219	TA 6.2.3.1.4. FAE P	Article/Périodique	Bibliothèque FARES	Tabac	Consultation sur place Exclu du prêt

Aucun avis, veuillez vous identifier pour ajouter le vôtre !